期刊文献+

MicroRNA-221对非小细胞肺癌NCI-H1299细胞生长的影响及其机制研究 被引量:5

Effect of microRNA-221 on NCI-H1299 Cell Growth in Non-small-cell Lung Cancer
下载PDF
导出
摘要 目的研究microRNA-221(miRNA-221)对非小细胞肺癌NCI-H1299细胞株生长调节的影响。方法通过转染miR-221-mimics或miR-221-inhibitor建立miRNA-221过表达或下调的NCI-H1299细胞系;通过MTT试验和Brd U插入染色检测细胞活力和增殖能力的变化;使用Q-PCR和western blot检测增殖相关基因mRNA或蛋白表达的变化。结果 miRNA-221过表达能够增强NCI-H1299细胞的活力和增殖能力(P<0.01);P27是NCI-H1299细胞中miRNA-221的潜在靶基因,同时P27蛋白水平中也被miRNA-221负调控(P<0.01)。结论 miRNA-221可以促进非小细胞肺癌NCI-H1299细胞的生长,可作为非小细胞肺癌基因治疗的有效靶点。 Objective To investigate effect of microRNA-221( miR-221) on growth regulation function of cell line NCI-H1299 in non-small-cell lung cancer( NSCLC). Methods NCI-H1299 cell lines of over-expressed miRNA-221 and down-regulated NCI-H1299 were established by transfecting miRNA-221 mimics or miR-221-inhibitor. Changes of cell viability and reproductive activity were detected using thiazolyl blue( MTT) assay and Brd U immunostaining method. The mRNA and albumen expression changes of related proliferation genes were detected using quantitative-polymerase chain reaction( Q-PCR) and western blot methods. Results Over-expressed miRNA-221 led to enhancement of cell viability and reproductive activity of NCI-H1299 cells( P〈0. 01). P27 was a potential target gene of miRNA-221 in NCIH1299 cell,and P27 was negatively regulated by miRNA-221 in the protein level( P〈0. 01). Conclusion MiR-221 can enhance the growth of cell line NCI-H1299 in non-small-cell lung cancer,and therefore it can be used as an effective target for gene therapy of non-small-cell lung cancer.
出处 《解放军医药杂志》 CAS 2016年第6期36-40,共5页 Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金 湖北省卫生厅医学科技攻关计划项目(120290)
关键词 微RNAS 非小细胞肺 基因表达 MicroRNAs Carcinoma non-small-cell lung Gene expression
  • 相关文献

参考文献26

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [J]. CA Cancer J Clin, 2010,60(5) :277-300.
  • 2Chansky K, Sculler J P, Crowley J J, et al. The interna- tional association for the study of lung cancer staging pro- ject: prognostic factors and pathologic TNM stage in sur- gically managed non-small cell lung cancer [ J ]. J Thorac Oncol, 2009,4 ( 7 ) :792-801.
  • 3李小江,贾英杰.非小细胞肺癌生存分析[J].天津中医药,2013,30(9):531-533. 被引量:7
  • 4Lin P Y, Yu S L, Yang P C. MicroRNA in lung cancer [J]. Br J Cancer, 2010,103(8) :1144-1148.
  • 5韩晓红,张宁宁,石远凯.非小细胞肺癌基因检测的临床意义[J].中国新药杂志,2013,22(17):2021-2026. 被引量:6
  • 6姚舒洋,张毅,支修益.非小细胞肺癌的靶向治疗策略[J].临床药物治疗杂志,2013,11(4):38-41. 被引量:2
  • 7张娜,王文彤,陶遵威.非小细胞肺癌分子靶向治疗的最新研究进展[J].天津药学,2015,27(1):44-46. 被引量:10
  • 8Ambros V. The functions of animal microRNAs [ J ]. Na- ture, 2004,431 ( 7006 ) :350-355.
  • 9Bartel D P. MicroRNAs: genomics, biogenesis, mecha- nism, and function[ J]. Cell, 2004,116 (2) :281-297.
  • 10Lewis B P, Shih I H, Jones-Rhoades M W, et al. Pre- diction of mammalian microRNA targets [ J ]. Cell, 2003, 115(7) :787-798.

二级参考文献131

  • 1贾英杰,张莹,孙一予,陈军.消岩汤不同时段参与化疗治疗非小细胞肺癌临床疗效观察[J].天津中医药大学学报,2006,25(3):164-165. 被引量:14
  • 2Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008[J]. Eur J Cancer, 2010,46(4): 765-78l.
  • 3Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002 346(2): 92-98.
  • 4Goss GD, Lorimer I, Tsao MS, et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IlIA non-small cell lung cancer(NSCLC): NCIC CTG BR.19[EB\OL]. J Clin Oncol, 2010, 28(18s): suppl: abstr LBA 7005. http://meeting.ascopubs.org/cgi/content/abstractI28/ 18_suppl/LBA 7005.
  • 5Mok TS, Wu YL, Thongprasert Set, al. Gefitinib or carboplatin?paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10): 947-957.
  • 6Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WITOG3405): an open label, randomised phase 3 trial[]]. Lancet Oncol, 2010,11(2): 121-128.
  • 7Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial[J]. 1 Clin Oncol, 2012, 30(24): 3002-301l.
  • 8Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation?positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyj.l], Lancet Oncol, 2011, 12(8): 735-742.
  • 9Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. N Engl 1 Med, 2006, 355(24): 2542-2550.
  • 10Shaw AT, Yeap BY, Solomon Bl, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis[J]. Lancet Oneal, 2011,12(11): 1004-1012.

共引文献96

同被引文献43

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部